• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email
    SC 13G/A 1 ea0220738-sc13ga1sands_nurix.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Nurix Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per shares

    (Title of Class of Securities)

     

    67080M103

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐Rule 13d-1(b)
      ☐Rule 13d-1(c)
      ☒Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Arthur T. Sands

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    3,272,832(1)

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    3,272,832(1)

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,272,832(1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.7%(2)

     

    12

    TYPE OF REPORTING PERSON

    IN

     

     

    (1)Includes (i) 308,333 shares of common stock, (ii) 2,364,499 shares underlying options to purchase common stock that are exercisable within 60 days of September 30, 2024, and (iii) 150,000 shares of common stock held by each of CMS Family Trust DTD, EES Family Trust DTD, IGS Family Trust DTD and LAS Family Trust DTD. Dr. Sands is the trustee of the CMS Family Trust, EES Family Trust, IGS Family Trust and LAS Family Trust.
      
    (2)Based on 67,098,027 shares of the Issuer’s Common Stock outstanding as of September 30, 2024.

     

     

     

     

    CUSIP No. 67080M103

    13G

     

    Page 3 of 5 Pages

      

    Item 1(a) Name of Issuer:
       
      Nurix Therapeutics, Inc.
       
    Item 1(b) Address of Issuer’s Principal Executive Offices:
       
      1700 Owens Street, Suite 205
      San Francisco, CA 94158
       
    Item 2(a) Name of Person Filing:
       
      Arthur T. Sands
       
    Item 2(b) Address of Principal Business Office or, If None, Residence
       
      c/o Nurix Therapeutics, Inc.
      1700 Owens Street, Suite 205
      San Francisco, CA 94158
       
    Item 2(c) Citizenship:
       
      United States
       
    Item 2(d) Title of Class of Securities:
       
      Common Stock, $0.001 par value per share
       
    Item 2(e) CUSIP Number:
       
      67080M103
       
    Item 3. Not applicable.

     

    Item 4. Ownership
         
      (a) Amount Beneficially Owned:  
         
        3,272,832(1)
         
      (b) Percent of Class:
         
        4.7%(2)
         
      (c)   Number of shares as to which the person has:
         
      (i) Sole power to vote or direct the vote:  
           
          3,272,832(1)
           
      (ii) Shared power to vote or direct the vote:
           
          0
           
      (iii) Sole power to dispose or to direct the disposition of:
           
          3,272,832(1)
           
      (iv) Shared power to dispose or to direct the disposition of:
           
          0

     

    (1) Includes (i) 308,333 shares of common stock, (ii) 2,364,499 shares underlying options to purchase common stock that are exercisable within 60 days of September 30, 2024, and (iii) 150,000 shares of common stock held by each of CMS Family Trust DTD, EES Family Trust DTD, IGS Family Trust DTD and LAS Family Trust DTD. Dr. Sands is the trustee of the CMS Family Trust, EES Family Trust, IGS Family Trust and LAS Family Trust.
       
    (2) Based on 67,098,027 shares of the Issuer’s Common Stock outstanding as of September 30, 2024.

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 4 of 5 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following:  ☒

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not applicable.
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certifications
       
      Not applicable.

     

     

     

     

    CUSIP No. 67080M1039

    13G

     

    Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024  
     
      By: /s/ Arthur T. Sands
      Name: Arthur T. Sands

     

     

    Get the next $NRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    10/11/2024$41.00Buy
    Jefferies
    9/6/2024$26.00Outperform
    Robert W. Baird
    7/31/2024$36.00Buy
    Truist
    6/26/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Director

      6/13/25 4:01:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

      Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

      6/12/25 6:59:59 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

      SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy. Details of the webcast and conference call are as follows: Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST Access details: The live webcast will be a

      6/6/25 7:00:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Silva Paul M

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      5/19/25 5:33:49 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kunkel Lori Anne

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      5/19/25 5:33:36 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gregory Julia P

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      5/19/25 5:33:24 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    SEC Filings

    See more
    • Nurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

      6/12/25 8:02:05 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

      5/19/25 4:08:19 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

      SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      5/12/25 10:44:45 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

      4/8/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

      SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board

      3/13/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

      Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 in CLL Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom's Macroglobulinemia Announced the appointment of John Northcott as Chief Commercial Officer Well capitalized with cash and marketable securities of $609.6 million SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial

      1/28/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 9:00:57 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 4:21:48 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 4:08:39 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Nurix Therapeutics with a new price target

      Leerink Partners initiated coverage of Nurix Therapeutics with a rating of Market Perform and set a new price target of $16.00

      3/17/25 7:40:03 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Nurix Therapeutics with a new price target

      BTIG Research initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00

      12/10/24 8:32:11 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Nurix Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $35.00

      12/6/24 7:59:04 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Financials

    Live finance-specific insights

    See more
    • Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

      Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

      6/12/25 6:59:59 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

      SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy. Details of the webcast and conference call are as follows: Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST Access details: The live webcast will be a

      6/6/25 7:00:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

      Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d

      6/16/24 5:30:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care